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14 Oral Presentations(expressed hereafter as mean6SEM pg/ml) in individual samples of
the discovery set confirming that they were significantly higher in
sGVHD compared to giGVHD or –GVHD plasma, respectively
(13,31262456 vs 39686537 vs 32576332, p\.0001). In samples
available from 113 sGVHD and 256 –GVHD patients, we deter-
mined whether elafin levels measured 7 days prior to clinical onset
predicted a subsequent occurrence of sGVHD; they were 1.26 fold
higher in patients who developed sGVHD (42796222 vs
34486108, p5 .001). We then analyzed a validation set of 429 pa-
tients: 275 (64%) –GVHD and 154 (36%) sGVHD. There were no
significant differences for patient characteristics and sample collec-
tion between groups. Elafin levels were two fold higher in sGVHD
plasma as compared to –GVHD plasma (75326488 vs 39256112,
p\.0001). We analyzed whether elafin levels provided prognostic
information regarding eventual maximum stage, transplant-related
mortality (TRM) and overall survival (OS).We divided the patients
using a threshold level of elafin that provided 85% specificity (5500
pg/ml). The group with the high levels of elafin (elafinhigh) com-
prised 29% of the population and developed more severe
skin GVHD than the group with low levels, experienced
significant greater TRM and lower OS; these differences remained
significant when adjusted for age, conditioning intensity, donor and
HLA-match.
Table 1. Correlating low/high elafin withmaximum skin stage,
TRM and OS
Maximumskin
stagep-
value*1 year
TRMp-
value*4 years
OSp-
value*0-1 2-4Low elafin
(%, 95% CI)83%
(78-87%)17%
(13-22%)\ 0.001 7%
(4-11%)0.008 35%
(27-36%)0.001High elafin
(%, 95%
CI)39%
(30-48%)61%
(52-70%)18%
(11-25%)53%
(47-60%)*p-value is adjusted for age, conditioning intensity, donor and HLA
match
Within the 154 patients with sGVHD, those elafinhigh had a mor-
tality-hazard ratio of 1.98 (p 5 .003) that remained significant (p 5
.017) after adjusting for stage of sGVHD, demonstrating an inde-
pendent association of mortality risk with elafin levels. We conclude
that elafin is a novel biomarker for sGVHD that can provide impor-
tant predictive, diagnostic and prognostic information, including
long term survival.31
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Regulatory CD41CD251Foxp31 T cells (Tregs) and regulatory
natural killer T (NK T) cells have each been shown to regulate
graft-versus-host disease (GVHD), and interactions between NK T
cells andTreg populations via IL-2 pathways has been shown in vitro
or related tomyasthenia gravis protection in syngeneicmurinemodel
systems. Though we have previously demonstrated interactions be-
tween these two regulatory cell populations after MHC-mismatched
allogeneic bonemarrow transplantation (allo-BMT) (ASBMT2007),
the mechanisms of this interaction were not previously known. We
now show that host NKT cells can mediate, via cytokine secretion,
the in vivo proliferative expansion of potent donor Treg allosuppres-
sors that prevents lethal GVHD inmice after conditioning with frac-
tionated lymphoid irradiation (TLI) and anti-T cell serum (ATS)
followedbyMHC-mismatched allo-BMT.Protection fromday6do-
nor CD81T cell proliferation by in vivo CFSE dilution, histopatho-
logic evidence of tissue injury in colon, and significant day 6
proliferation of donor Tregs, all features seen in wild-type TLI/ATS conditioned hosts, were lost in TLI/ATS-treatedNKT cell-de-
ficient Jalpha18-/- hosts (p\ 0.01) and IL-4-/- hosts (p\ 0.01), or
when CD41CD251T cells were depleted from the donor transplant
(p\0.01). Chimeric donor Tregs expanded in vivo after TLI’/ATS
and allo-BMT were potent suppressors of donor responders in 72-
hour MLR against host or third-party stimulators, comparable to
wild-type sorted Treg. Add-back of wild-type donor CD41CD251
T cells to the CD25-depleted donor transplant or add-back of wild-
type (p 5 0.001) but not IL-4-/- (p 5 0.11) host NKT cells to NK
T-deficient hosts restored both donor Treg proliferation and protec-
tion fromday 6 donorCD81Tcell proliferation, indicating that host
NKT cell-induced proliferation of donor Tregs and protection from
donor CD8-mediated colitis was IL-4-dependent. In conclusion, our
findings show that transplantation strategies designed to preserve
host regulatory cells can augment in vivo donor Treg expansion
through an IL-4 dependent mechanism after allogeneic hematopoi-
etic cell transplantation (HCT), and demonstrate mechanisms by
which key host and donor regulatory populations can form
an immunoregulatory bridge helping to cross MHC barriers to
regulate GVHD after allogeneic BMT.32
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Background:Although the activating killer Ig-like receptor (KIR)
3DS1 has been implicated in malignancies, infections, and autoim-
mune diseases, the data for a clinical impact of donor KIR 3DS1 in
the hematopoietic cell transplantation (HCT) setting are heteroge-
nous. We determined the influence of donor activating KIR on risks
of GVHD, relapse, and mortality in a large cohort of unrelated
transplants facilitated by the NMDP.
Methods:Donor KIR typing was performed for 1092 patients re-
ceiving transplants between 1995 and 2002 from 9/10 or 10/10HLA
allele matched unrelated donors following myeloablative condition-
ing for the treatment of hematologicmalignancies with data provided
by theCIBMTR.59%of transplantswere 10/10matchedwith typing
verified through the NMDP retrospective typing program. Cox re-
gression was used to examine the association between KIR and
HCT outcome. Models were adjusted for age, disease severity, do-
nor/patient gender, T-cell depletion, stem cell source, conditioning,
and degree of HLA mismatch.
Results: 34% (n5 364) of donors were KIR 3DS1 positive. The
presence of donor 3DS1 was associated with a statistically signifi-
cant decrease in grade II-IV acute GvHD [OR 0.71 (0.55–0.92,
p 5 0.009)] and a suggestive association with decreased mortality
[HR 0.86 (0.74–1.01, p 5 0.07)], but relapse was similar [HR
0.97 (0.73–1.29, p 5 0.82)]. Because 3DS1 defines a subset of
KIR B haplotypes, we examined the influence of donor KIR haplo-
types on outcomes. Although there was a trend, donor KIR haplo-
type B (AB, BB, BX; n5 714) was not associated with a statistically
significant decrease in grade II-IV aGvHD compared to donor AA
haplotypes [OR 0.87 (0.74–1.0 3, p 5 .10)]. Grade II-IV aGvHD
was similar for donor B haplotypes lacking 3DS1 (n 5 350) com-
pared to the AA haplotype or B haplotype with 3DS1 [OR 1.05
(0.89–1.2 4, (p 5 0.54)], but B haplotypes lacking 3DS1 had a sug-
gestively higher rate of grade II-IV aGvHD compared to B haplo-
types with 3DS1 [OR 1.20 (0.99–1.4 6, (p5 0.07)]. The presence of
other activating KIR (2DS1, 2DS2, 2DS3) was not statistically
significantly associated with HCT outcome. KIR 2DS5, however,
was associated with a trend toward decreased mortality [HR 0.85
(0.72–1.0 1, p 5 0.07)].
Conclusion: For patients with hematologic malignancies receiv-
ing an unrelated HCT, presence of donor KIR 3DS1 was associated
with less grade II-IV acute GvHD and may be associated with
improved survival.
